Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,755.20
(
-0.17%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.43
(
-2.02%
)
Bitcoin
69,826.50
(
-1.97%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 159060

Sunday, 03/31/2013 2:07:37 PM

Sunday, March 31, 2013 2:07:37 PM

Post# of 257262

It isn't Gilenya's price that prevents usage…

Then why did you highlight the pricing comparison between Gilenya and Tecfidera in the first sentence of #msg-86271444?

You are correct that historically patients did not change MS drugs often. Sadly, that was yesterday.

I don’t understand your use of the word sadly in this context, nor do I agree that the “stickiness” of the MS market is a thing of the past.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now